Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors

Published

August 18, 2020

Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors

When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond Deegan knew exactly what to do. She turned to a network of colleagues she developed through her past participation in the Executive Women In Bio Boardroom Ready Program…

MORERelated News
Native mass spectrometry: Drug discovery’s new kid on the block
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...